We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Altimmune (ALT) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Altimmune, Inc. (ALT - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Altimmune, Inc. is one of 1180 individual stocks in the Medical sector. Collectively, these companies sit at #9 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Altimmune, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ALT's full-year earnings has moved 19.9% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, ALT has returned 28.5% so far this year. At the same time, Medical stocks have lost an average of 14.6%. This shows that Altimmune, Inc. is outperforming its peers so far this year.
Chinook Therapeutics is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 10.4%.
For Chinook Therapeutics, the consensus EPS estimate for the current year has increased 17.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Altimmune, Inc. belongs to the Medical - Drugs industry, which includes 231 individual stocks and currently sits at #142 in the Zacks Industry Rank. Stocks in this group have lost about 21.4% so far this year, so ALT is performing better this group in terms of year-to-date returns. Chinook Therapeutics is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to Altimmune, Inc. and Chinook Therapeutics as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Altimmune (ALT) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Altimmune, Inc. (ALT - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Altimmune, Inc. is one of 1180 individual stocks in the Medical sector. Collectively, these companies sit at #9 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Altimmune, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ALT's full-year earnings has moved 19.9% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, ALT has returned 28.5% so far this year. At the same time, Medical stocks have lost an average of 14.6%. This shows that Altimmune, Inc. is outperforming its peers so far this year.
Chinook Therapeutics is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 10.4%.
For Chinook Therapeutics, the consensus EPS estimate for the current year has increased 17.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Altimmune, Inc. belongs to the Medical - Drugs industry, which includes 231 individual stocks and currently sits at #142 in the Zacks Industry Rank. Stocks in this group have lost about 21.4% so far this year, so ALT is performing better this group in terms of year-to-date returns. Chinook Therapeutics is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to Altimmune, Inc. and Chinook Therapeutics as they could maintain their solid performance.